Rheumatology Centre, Pierre Paul Riquet Hospital, Toulouse University Hospital & Paul Sabatier University, 1 Place du Dr Baylac, 31059, Toulouse, France.
Center for Pathophysiology of Toulouse Purpan, INSERM UMR 1043, CHU Purpan, Toulouse, France.
Osteoporos Int. 2019 Jun;30(6):1235-1241. doi: 10.1007/s00198-019-04918-7. Epub 2019 Mar 7.
Little is known about osteoporosis in mast cell disorders (MCDs) not related to systemic mastocytosis. We described osteoporosis and fractures in MCDs and showed that systemic mastocytosis was the only studied MCDs associated with osteoporotic vertebral fractures.
To describe osteoporosis (OP) and fragility fractures in mast cell disorders (MCDs).
We retrospectively analyzed data concerning all successive patients with systemic mastocytosis (SM), cutaneous mastocytosis (CM), and mast cell activation syndromes (MCAS) diagnosed in our mastocytosis expert center between 2004 and 2015. We collected data concerning demographic profiles, clinical signs of MCD, osteoporosis, fractures, densitometry, and biological assessment of MCD. We compared CM and MCAS patients with SM patients with regard to the characteristics of OP and fragility fractures.
We assessed 89 SM patients, 20 CM patients, and 20 MCAS patients. Osteoporosis was less frequent in CM (15.0%) and MCAS (10.0%) than in SM (44.9%). Similarly, fractures were less frequent in non-SM MCDs, respectively 5.0%, 5.0%, and 28.1%. SM patients displayed high prevalence of vertebral fractures (22.5%), mostly multiple. Conversely, in non-SM patients, vertebral fractures appeared to be uncommon (5%) and more frequently associated with risk factors for osteoporosis.
SM is associated with multiple vertebral osteoporotic fractures, whereas CM and MCAS do not appear to be associated with this phenotype.
尚不清楚与系统性肥大细胞增多症无关的肥大细胞疾病(MCD)中的骨质疏松症。我们描述了 MCD 中的骨质疏松症和骨折,并表明系统性肥大细胞增多症是唯一研究的与骨质疏松性椎体骨折相关的 MCD。
描述肥大细胞疾病(MCD)中的骨质疏松症(OP)和脆性骨折。
我们回顾性分析了 2004 年至 2015 年期间在我们的肥大细胞专家中心诊断的系统性肥大细胞增多症(SM)、皮肤肥大细胞增多症(CM)和肥大细胞激活综合征(MCAS)的所有连续患者的数据。我们收集了有关人口统计学特征、MCD 的临床体征、骨质疏松症、骨折、骨密度测定和 MCD 的生物学评估的数据。我们比较了 CM 和 MCAS 患者与 SM 患者的 OP 和脆性骨折特征。
我们评估了 89 例 SM 患者、20 例 CM 患者和 20 例 MCAS 患者。CM(15.0%)和 MCAS(10.0%)中的骨质疏松症发生率低于 SM(44.9%)。同样,非 SM MCD 中的骨折发生率也较低,分别为 5.0%、5.0%和 28.1%。SM 患者表现出高的椎体骨折发生率(22.5%),主要是多发性的。相反,在非 SM 患者中,椎体骨折似乎不常见(5%),并且更常与骨质疏松症的危险因素相关。
SM 与多发性椎体骨质疏松性骨折相关,而 CM 和 MCAS 似乎与这种表型无关。